Skip to content

Effects of CPET-based precise individualized aerobic exercise prescription on hyperuricemia

Effects of CPET-based precise individualized aerobic exercise prescription on hyperuricemia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800016859
Enrollment
Unknown
Registered
2018-06-29
Start date
2018-06-01
Completion date
Unknown
Last updated
2018-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperuricemia

Interventions

Case series:aerobic exercise

Sponsors

Beijing Xiaotangshan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. The applicant complies with the above inclusion criteria but does not agree to sign the informed consent; 2. Persons with unstable hemodynamics; 3. Individuals with significant psychiatric symptoms or cognitive impairment; 4. Persons who stay in bed for a long time or cannot train for a treadmill because of the original disease; 5. Humanoid severe infection; 6. A person with significant cardiac, lung, liver and kidney dysfunction; 7. People who are not cooperating with the slash for other reasons.

Exclusion criteria

Exclusion criteria: The applicant complies with the above inclusion criteria but does not agree to sign the informed consent; Persons with unstable hemodynamics; Individuals with significant psychiatric symptoms or cognitive impairment; Persons who stay in bed for a long time or cannot train for a treadmill because of the original disease; Humanoid severe infection; A person with significant cardiac, lung, liver and kidney dysfunction; People who are not cooperating with the slash for other reasons.

Design outcomes

Primary

MeasureTime frame
Uric acid;VO2;AT;VO2max/VO2pred (%);

Countries

China

Contacts

Public ContactHu Ling

Beijing Xiaotangshan Hospital

lydhzw@126.com+86 01061789928

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026